Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
JPRN |
Last refreshed on:
|
17 October 2023 |
Main ID: |
JPRN-UMIN000014709 |
Date of registration:
|
01/08/2014 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I
|
Scientific title:
|
Study on Parkinson's disease and related disorders with dopamine transporter ligand [C-11]PE2I - DAT PET with [C-11]PE2I in PD and related disorders |
Date of first enrolment:
|
2014/07/01 |
Target sample size:
|
200 |
Recruitment status: |
Complete: follow-up complete |
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017098 |
Study type:
|
Interventional |
Study design:
|
Single arm Non-randomized
|
Phase:
|
Not selected
|
|
Countries of recruitment
|
Japan
| | | | | | | |
Contacts
|
Name:
|
Kenji
Ishii |
Address:
|
Itabashi-ku
Japan |
Telephone:
|
0339643241 |
Email:
|
ishii@pet.tmig.or.jp |
Affiliation:
|
Tokyo Metropolitan Institute of Gerontology Research Team for Neuroimaging |
|
Name:
|
Kenji
Ishii |
Address:
|
35-2, Sakae-cho, Itabashi-ku, Tokyo
1730015
Japan |
Telephone:
|
0339643241 |
Email:
|
ishii@pet.tmig.or.jp |
Affiliation:
|
Tokyo Metropolitan Institute of Gerontology Research Team for Neuroimaging |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1.The subject who has dysfunction in the liver / kidney. 2.The subject who has abnormal findings in the central nervous system other than the target disorders. 3.The subjects having cardiac failure. 4.The subject with a history of a drug or food allergy. 5.Pregnant or woman who has a chance of pregnant. 6.The subject who was judged by the clinical investigator to be inappropriate as a participant in this study.
Age minimum:
18years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
Health Condition(s) or Problem(s) studied
|
Patients of Parkinson's disease and related disorders
|
Intervention(s)
|
The dosage in the vein of [C-11]PE2I, [C-11]raclopride, and [F-18]FDG for PET/CT imaging.
|
Primary Outcome(s)
|
Binding potential and tissue concentration ratio
|
Source(s) of Monetary Support
|
None
|
Ethics review
|
Status: YES
Approval date: 12/06/2014
Contact:
naomi_hasegawa@tmghig.jp
Ethics Committee, Tokyo Metropolitan Institute of Gerontology
0339643241
naomi_hasegawa@tmghig.jp
|
Results
|
Results available:
|
Yes |
Date Posted:
|
|
Date Completed:
|
30/09/2019 |
URL:
|
|
|
|